Reading room
Reports, issues, and source logs.
Start with the dated evidence audits, explainers, and field guides below, then use the Library and Claim Check for the current source record. Website publication and newsletter delivery are separate: a piece can be live here without having been emailed. Follow the RSS feed for the dated site record.
Live CurrentOfficial-source reporting that updates when the public record changes.
Dated issuesEvidence audits and explainers that passed independent review.
Receipts attachedSource logs show the claims, limits, and corrections behind the work.
Live Current · independently verified
FDA · July 23–24, 2026
All fourteen form-specific tallies are recorded from FDA’s exact questions and FDA-linked archived broadcasts. Six peptide groups were recommended for inclusion and emideltide against; every final FDA determination remains pending.
Issue 01 · independently reviewed
BPC-157 status
Category 2 removal, the July advisory votes, and FDA's still-pending final determination are separate events. None verifies the identity or quality of an online product.
Published on site · not emailed
Peptide Science
Issue 02 turns the paper count into an evidence funnel: one uncontrolled human musculoskeletal report, no controlled tendon-repair trial, and a regulatory review scoped much more narrowly than the online claims.
Published on site · not emailed
Milestone Decoder
Issue 03 separates a trial result, an FDA application, product approval, and product identity—using CagriSema, retatrutide, and mazdutide as three different records rather than one “next GLP-1” bucket.
Field guide · official sources
FDA vote decoder
A plain-language guide to what PCAC does, what the 503A Bulks List is, what the July votes changed, and what still requires a later FDA action.
The site is already the publication.
The email edition is an optional delivery layer and remains off until its postal-address, welcome, mobile, and unsubscribe tests pass.
Join the early list